Bloodstream Infection Clinical Trial
Official title:
Feasibility of Hemodialysis With the GARNET Device in Chronic Hemodialysis Patients With a Bloodstream Infection
To evaluate the feasibility of performing combined hemodialysis with the GARNET device in chronic hemodialysis patients with a blood stream infection (BSI), and measure clinical performance and safety endpoints.
Status | Recruiting |
Enrollment | 15 |
Est. completion date | December 31, 2021 |
Est. primary completion date | October 15, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility | Inclusion Criteria: 1. Hospitalized adults (age = 18 years and = 90 years) 2. Patients on chronic hemodialysis for = 3 hours per treatment and a minimum of 3 times per week schedule 3. Suspected or confirmed BSI as defined by: a. For a suspected central-line (temporary or tunneled central venous catheters) and non- central line (arterio-venous fistula and arterio-venous graft) vascular infection: i. presence of at least one of the following signs or symptoms: 1. fever (>38.0°C), 2. pain*, 3. erythema*, or 4. heat at involved vascular site* (*with no other recognized cause); or ii. presence of purulent drainage/pus at the vascular site, in accordance with the CDC/NHSN Surveillance Definitions for Specific Types of Infections b. For other suspected infections: i. presence of at least 2 of the 4 SIRS criteria: 1. Body temperature > 101°F (38.3°C) or < 96.8°F (36°C); 2. Heart rate > 90 beats per minute; 3. Respiratory rate > 20 breaths per minute; 4. White blood cell count > 12,000/mm³, < 4,000/mm³, or > 10% bands c. For confirmed infections: i. laboratory-confirmed BSI based on the isolation of an organism from blood cultures; or ii. If a laboratory-confirmed BSI due to a commensal organism, the presence of at least one of the following signs or symptoms will be required: fever (>38.0°C), chills, or hypotension. 4. Subject agrees to comply with all follow-up evaluations 5. Subject has provided written informed consent; or if unable to perform informed consent, written informed consent on behalf of the subject has been provided by a legally-authorized representative. Exclusion Criteria: 1. Pregnancy confirmed by positive urine or serum test, or lactating mothers 2. Subject with severe concomitant disease expected to prolong hospitalization or cause death in = 30 days, or terminal illness, or "do not resuscitate" code status 3. Known sensitivity/allergy to heparin 4. Known sensitivity/allergy to polyethersulfone dialyzers 5. Active bleeding (e.g. active GI bleeding, hematuria or epistaxis, untreated coagulopathy or bleeding from a non-compressible site) 6. Severe thrombocytopenia (platelet count < 50,000/µL) 7. Active enrollment in another study (patients enrolled in an observational study without any interventions or in post-market surveillance do not need to be excluded) 8. Inability to achieve vascular access blood flow rates of =250mL/min during the previous dialysis treatment 9. Requirement for Continuous Renal Replacement Therapy/Sustained Low Efficiency Dialysis (CRRT/SLED) due to hemodynamic instability 10. Hemodynamic instability 11. Medical conditions requiring regular blood transfusion 12. Hypocalcemia or clinical symptoms of hypocalcemia at time of enrollment 13. History of or known hypercoagulable state (e.g. Systemic Lupus Erythematosus (SLE), antiphospholipid syndrome/lupus anticoagulant, protein C or S deficiency, antithrombin deficiency, factor V Leiden deficiency, active cancer, sickle cell disease, and history of deep vein thrombosis (DVT)) 14. History of a condition documented in the medical record within 6 months prior to enrollment that may result in an increased risk for thrombosis, including any of the following: 1. Multiple incidents (= 2) of unresolvable thrombosis-induced catheter malfunctions which required catheter exchange, occurring within the 6 months prior to enrollment 2. Prior history of renal transplant thrombosis 3. Elevated Factor VIII with or without familial hypercholesterolemia 4. Hyperhomocysteinemia with a homocysteine level of >4 mg/L (17.2 µmol/L) 15. Currently taking oral contraception |
Country | Name | City | State |
---|---|---|---|
United States | University of Maryland at Baltimore | Baltimore | Maryland |
United States | Walter Reed National Military Medical Center | Bethesda | Maryland |
United States | Beth Israel Deaconess Medical Center | Boston | Massachusetts |
United States | Houston Methodist | Houston | Texas |
United States | Oregon Health and Science University | Portland | Oregon |
United States | George Washington University | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Boa Biomedical, Inc. | Avania |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety - Rate of adjudicated device- or GARNET device procedure-related Serious Adverse Events (SAEs) | Rate of adjudicated device or GARNET device procedure-related Serious Adverse Events (SAEs) All primary safety endpoints will be reported as adjudicated by the designated Clinical Events Committee (CEC) during treatment and through the 30-day follow-up period. | 30-day follow-up post-2nd GARNET device treatment | |
Secondary | Resolution of Blood Stream Infection at 30-days post 2nd GARNET device treatment | • Resolution of Blood Stream Infection | 30-day follow-up post-2nd GARNET device treatment | |
Secondary | Clearance for small (blood urea nitrogen) and middle (beta-2-microglobulin) molecule solutes by the GARNET device, as measured by the intra-dialytic urea and beta-2-microglobulin reduction ratio. | • Extent of clearance of solutes (small and middle molecules) | During Week 1 participation - Day 0: pre and post first GARNET device treatment and pre and post second GARNET device treatment which must occur by Day 7. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Completed |
NCT02400268 -
Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae
|
Phase 3 | |
Recruiting |
NCT04070820 -
Combination Treatment for Enterococcus Faecalis Bacteriemia Multicenter, Observational Study"
|
||
Completed |
NCT03147807 -
BetaLACTA® Test for Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections in ICU
|
N/A | |
Completed |
NCT05411315 -
Pragmatic Randomized Trial for Arterial Catheters in the Critical Care Environment
|
N/A | |
Enrolling by invitation |
NCT05880069 -
Clinical Outcomes in Patients With Infection by Resistant Microorganism
|
||
Terminated |
NCT04250168 -
Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
|
||
Terminated |
NCT04876430 -
Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems
|
Phase 2/Phase 3 | |
Completed |
NCT03255759 -
Actionable Results: Bloodstream Infection Molecular Assay Evaluation
|
N/A | |
Active, not recruiting |
NCT03744728 -
Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures
|
N/A | |
Terminated |
NCT00680459 -
Ethanol Locks for the Treatment of Central Venous Line Infections
|
Phase 3 | |
Recruiting |
NCT04839653 -
Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria
|
N/A | |
Recruiting |
NCT03896893 -
Neonatal Bacterial Colonization Study
|
N/A | |
Completed |
NCT05277350 -
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT00843804 -
Surveillance for Nosocomial Infections in Pediatric Cancer Patients
|
N/A | |
Completed |
NCT00467272 -
Catheter Related - Gram Positive Bloodstream Infections
|
Phase 2 | |
Completed |
NCT04710212 -
Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
|
||
Not yet recruiting |
NCT06271031 -
Process Mapping and Data Collection to Inform a Computer Simulation Model of Hospitalised Patients With Bloodstream Infection, Sepsis and Systemic Infection
|
||
Not yet recruiting |
NCT03991793 -
Granzyme A in Patients With E. Coli Bacteremic Urinary Tract Infections
|
||
Completed |
NCT00870623 -
Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections
|